Programs studying immune composition, activation, cytotoxicity and treatment response in tissue context.
R&D service
PDO 2.0 for immuno-oncology
Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures, with tissue imaging and functional assays tailored to your candidate.
View imageTissue, immune and treatment readouts
See immune context and treatment response in renal PDO 2.0
The renal PDO 2.0 study shows tumor and T-cell marker images from source tissue and culture, alongside flow results related to IL-2 stimulation and checkpoint blockade. Assays for a new candidate can focus on immune composition, activation or tumor response.
Study focus
Questions we can help answer
- 01What immune-cell populations are present in the tumor sample?
- 02How does treatment affect immune activation and cytotoxicity?
- 03How does tissue context shape response?
STUDY APPROACH
Match the model and assays to your program
Use conventional PDO for tumor-cell-focused efficacy and add PDO 2.0 when immune and tissue context are central to the study.
Histology, immunofluorescence, flow, tumor viability/apoptosis and cytokines selected from the sample baseline.
Baseline and vehicle, mechanism-relevant positive controls, monotherapy and combination arms with gating and analysis records.
Integrate tumor response, immune activation and secreted signals to compare treatment conditions and prioritize the strongest mechanism and follow-up studies.
Study workflow
From sample profiling to immunotherapy response
We tailor the model and assay plan to the candidate's mechanism and the sample's tissue and immune profiles. Options include PDO 2.0 / ALI, immune co-culture and combined study designs.
Candidate and sample profile
We review the modality, mechanism, tumor type, sample condition and prior therapy to select the immune questions and assays best suited to the study.
Model selection and immune baseline
Select PDO 1.0, PDO 2.0 / ALI or a project-specific co-culture, then establish a pretreatment baseline using histology, epithelial identity and markers such as CD3 and CD8.
Treatment and multimodal readouts
Set dose, time and appropriate controls, then combine viability, apoptosis, flow, histology, immunofluorescence, cytokine or TCR readouts around the mechanism.
Compare responses and plan next studies
Integrate tumor response, immune-cell changes, secreted signals and model QC to compare candidates and prioritize mechanism or confirmatory studies.
Study images and readouts
Tissue identity, immune context and function
Use tissue images, functional readouts and molecular assays to understand model identity, treatment response and differences across candidate strategies.
View imageImmune-stimulation context: CD3, PanCK and DAPI imaging with and without IL-2 shows immune and tumor-epithelial signals within the same PDO study.
TRiCBIO ccRCC PDO 2.0 immune-context study data
View imageTreatment-related readouts: PD-L1-, CD8- and CD56-associated flow profiles are interpreted alongside early-apoptosis and necrosis measurements to compare immune-associated and cell-death changes under immune-checkpoint blockade.
TRiCBIO ccRCC PDO 2.0 immune-context study dataExpected study outputs
What you receive
Model and immune baseline
Pretreatment QC covers model identity, tissue state and immune components selected for the study.
Tumor and immune response data
Results from the agreed assays, such as tumor viability, apoptosis, immune-cell profiling, histology or cytokine analysis.
Traceable data package & interpretation
Receive raw data, experimental conditions, analysis methods and a study report, with interpretation of how the findings support candidate comparison and next-step decisions.
Relevant model systems
Relevant model systems
The 2018 Cell study established the ALI tumor–immune organoid method. TRiCBIO applies it to tissue and immune profiling in colorectal, pancreatic, liver and renal cancer programs, defining the sample baseline, measurable endpoints, culture window and deliverables before treatment begins.
FAQ
Planning your study
Explore model selection, study planning and deliverables before your first discussion with our scientists.
Should an immuno-oncology study use PDO 1.0, PDO 2.0 or an immune co-culture?
Choose PDO 1.0 for tumor-cell-focused efficacy, PDO 2.0 / ALI for source-tissue and sample immune context, or a tailored co-culture when defined effector cells or ratios matter. Our scientists recommend the system based on sample condition, candidate mechanism and intended readouts.
What information is useful for an initial immuno-oncology discussion?
Start with non-confidential tumor and sample context, candidate modality and mechanism, available data, and the immune change you want to evaluate. The scientific team can then discuss the model, dose and timing, controls, and an appropriate combination of histology, flow, cytokine or functional assays.
What is typically delivered from an immuno-oncology study?
Typical deliverables include model and immune-baseline QC, raw data, representative images and a study report. The report connects tumor response, immune-cell changes and secreted signals, with analysis methods to help you compare candidates. Deliverables are agreed in the study plan.
PROJECT DISCUSSION
Plan an immuno-oncology study
Describe the tumor type, sample context, candidate mechanism and immune change of interest. Our scientists can recommend PDO 2.0 / ALI or a co-culture design with the corresponding assays.